|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1050 K STREET, NW, #800 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | RESEARCH TRIANGLE PARK |
State | NC |
Zip Code | 27709 |
Country | USA |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sarah J. Walsh, Vice President, Federal Government Relations Tax & Pharmaceuticals |
Date | 07/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Fiscal Year 2013 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act -
provisions relating to Ryan White CARE Act, FDA funding
Fiscal Year 2013 Department of Homeland Security Appropriations Act - provisions relating to Customs and Border Protection
Fiscal Year 2013 Labor-HHS-Education Appropriations Act - provisions relating to Vaccine Section 317 program, Ryan White CARE Act
H Con Res 112 Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate
budgetary levels for fiscal years 2014 through 2022 - provisions related to health care programs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
HR 3995 - Protect Consumers Access to Generic Drugs Act - provisions related to patent settlements
S. 1882 - Fair and Immediate Release of Generic Drugs Act - provisions related to patent settlements
HR 3497 - MODDERN Cures Act of 2011 - provisions related to data protection
S 27 - Preserve Access to Affordable Generics Act - provisions related to patent settlements
H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs -
provisions relating to authorized generics
HR 3261 - Stop Online Piracy Act - provisions related to anti-counterfeiting
S 373 - The Fair Prescription Drug Competition Act - provisions related to authorized generics
S 968 - Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011 - provisions
related to anti-counterfeiting
HR 2182,S 1734 - Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S 2236 - Advancing Breakthrough Therapies for Patients Act of 2012 - provisions related to FDA regulation
S 2113 - Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act - provisions related to
accelerated approval and other FDA matters
The Better Pharmaceuticals and Devices for Children Act - "Provisions related to o amending the Federal Food, Drug, and Cosmetic Act with respect to pediatric provisions"
HR 4272 - BPCA and PREA Reauthorization Act of 2012 - Provisions related to amending title IV of the Public Health
Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the
Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
HR 4156, S 2281 - Expanding and Promoting Expertise in Rare Treatments Act of 2012 - provisions related to strengthening
the FDA's ability to seek advice from external experts regarding rare diseases
HR 3214 - Food and Drug Administration Mission Reform Act of 2011- provisions to revise the mission of the Food and
Drug Administration
HR 4132 - FAST Act - provisions related to accelerated approval and other FDA matters
HR 3839 - Drug Shortage Prevention Act of 2012 - provisions related to prescription drug shortages
HR 2674 - 340B Program Improvement Act - provisions related to the 340B program
PL 111-148, PL 111-152 - Patient Protection and Affordable Care Act - ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation provisions
HR 2405, S 1855 - Pandemic and All Hazards Preparedness Act - provisions relating to influenza vaccine innovative
technologies
HR 4223, S 1002 - Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE
DOSES) - provisions related to supply chain security
HR 1483 - The Drug Safety Enhancement Act of 2011 - provisions related to supply chain security
HR 1930, S 1799 - Access to Appropriate Immunizations for Veterans Act of 2011- provisions related to extending VA
performance measure to include all federally recommended vaccine
HR 3202 - Water Protection and Reinvestment Act - provisions pertaining to pharmaceuticals in the environment
S 3397 - Secure and Responsible Drug Disposal Act - provisions related to safe drug disposal
S 319 - Pharmaceutical Market Access and Drug Safety Act of 2011 - provisions related to drug importation
HR 2245, S 296 - Preserving Access to Life-Savings Medicines Act of 2011 - provisions related to drug shortages
HR 2939 - Pharmaceutical Stewardship Act of 2011- provisions related to drug safety
Prescription Drug User Fee Act - issues related to reauthorization of the Prescription Drug User Fee Act
HR 2529, S 1368 - Restoring Access to Medication Act - provisions relating to reimbursement of OTC drugs under flexible
spending and health savings accounts
S 1584 - Drug Safety and Accountability Act of 2011- provisions related to drug safety
Federal Food, Drug, and Cosmetic Act - section related to FDA and regulation of nicotine replacement therapies
S. 1699 - Prescription Drug Cost Reduction Act - provisions related to 340B and drug rebates
S. 1752 - Freedom to Breath Act of 2011 - provisions relating to the removal of Essential-Use Designation for epinephrine.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S 1699 - Prescription Drug Cost Reduction Act - provisions related to Medicare Part B and drug rebates
HR 999 - Medicare Prescription Drug Savings and Choice Act of 2011- provisions related to Medicare Part D
HR 2190 - Medicare Drug Savings Act of 2011- provisions related to Medicare Part D
HR 2248 - Medicare Prescription Drug Price Negotiation Act of 2011- provision related to Medicare Part D
HR 3765 - Temporary Payroll Tax Cut Continuation Act of 2011- provisions related to Medicare
S 31 - Prescription Drug and Health Improvement Act of 2011-provisions related to Medicare Part D
S 44 - Medicare Prescription Drug Price Negotiation Act of 2011- provisions related to Medicare Part D
HR 452 - Medicare Decisions Accountability Act - provisions related to the Independent Payment Advisory Board (IPAB)
H.R. 5 - To improve patient access to health care services and provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system - provisions related to the Independent Payment Advisory Board (IPAB)
S 560 - Medicare Prescription Drug Savings and Choice Act of 2011- provisions related to Medicare Part D
S 668 - Health Care Bureaucrats Elimination Act - provisions related to the Independent Payment Advisory Board (IPAB)
S 1206 - Medicare Prescription Drug Savings Act of 2011- provisions related to Medicare Part D
S 1251 - Medicare and Medicaid FAST Act - provisions related to Part D issues
H.R. 1063 - Strengthening Medicare & Repaying Taxpayers Act of 2011 - provisions relating to reform of Secondary Payer
rules
S 365 - Budget Control Act of 2011 - provisions related to deficit reduction through Medicare and Medicaid
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 942 - American Research and Competitiveness Act of 2011- provisions relating to the research and development tax credit
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Pacific Strategic Economic Partnership Agreement (TPP) - provisions related to intellectual property, market access and public health
Russia Permanent Normal Trade Relations (PNTR) - "provisions related to lifting the restrictions of Title IV of the
Trade Act of 1974 as they apply to Russia, which includes the freedom-of-emigration requirements of the Jackson-Vranik amendment."
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |